Black Diamond Financials
| BDTX Stock | USD 2.65 0.08 3.11% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.48 | 6.8225 |
|
|
Investors should never underestimate Black Diamond's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Black Diamond's cash flow, debt, and profitability to make informed and accurate decisions about investing in Black Diamond Therapeutics.
Net Income |
|
Black | Select Account or Indicator |
Understanding current and past Black Diamond Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Black Diamond's financial statements are interrelated, with each one affecting the others. For example, an increase in Black Diamond's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Black Diamond's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Black Diamond Therapeutics. Check Black Diamond's Beneish M Score to see the likelihood of Black Diamond's management manipulating its earnings.
Black Diamond Stock Summary
Black Diamond competes with Passage Bio, Alector, Revolution Medicines, Stoke Therapeutics, and Adaptimmune Therapeutics. Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Black Diamond operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US09203E1055 |
| CUSIP | 09203E105 |
| Location | Massachusetts; U.S.A |
| Business Address | One Main Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.blackdiamondtherapeutics.com |
| Phone | 617 252 0848 |
| Currency | USD - US Dollar |
Black Diamond Key Financial Ratios
| Return On Equity | -0.63 | ||||
| EBITDA | (86.02 M) | ||||
| Net Income | (82.44 M) | ||||
| Cash Per Share | 4.43 X | ||||
| Debt To Equity | 0.19 % |
Black Diamond Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 158.3M | 329.7M | 247.7M | 156.3M | 158.6M | 174.5M | |
| Other Current Liab | 2.9M | 10.6M | 19.2M | 10.5M | 14.2M | 9.7M | |
| Net Tangible Assets | (47.2M) | 307.8M | 195.9M | 115.7M | 133.0M | 100.8M | |
| Net Debt | 45.9M | (25.9M) | (37.3M) | (6.2M) | (30.9M) | (29.4M) | |
| Retained Earnings | (51.0M) | (118.2M) | (243.8M) | (335.0M) | (417.4M) | (396.6M) | |
| Accounts Payable | 2.0M | 2.5M | 4.1M | 1.9M | 2.3M | 2.1M | |
| Cash | 154.7M | 34.6M | 65.8M | 34.3M | 56.2M | 63.7M | |
| Other Assets | 2.4M | 0.0 | 1.2M | 1.2M | 1.0 | 0.95 | |
| Capital Surpluse | 3.8M | 425.4M | 440.1M | 452.5M | 520.4M | 546.4M | |
| Other Current Assets | 1.0M | 4.5M | 5.9M | 4.9M | 2.6M | 3.0M | |
| Total Liab | 209.3M | 21.9M | 491.5M | 40.6M | 41.8M | 39.7M | |
| Net Invested Capital | (47.2M) | 307.8M | 195.9M | 115.7M | 116.7M | 104.8M | |
| Total Current Assets | 154.7M | 319.6M | 209.8M | 127.7M | 134.0M | 158.0M | |
| Net Working Capital | 150.9M | 305.3M | 192.1M | 112.4M | 114.4M | 146.1M |
Black Diamond Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 461K | 4.0M | 3.5M | 2.0M | 1.9M | 1.9M | |
| Interest Income | 461K | 4.0M | 3.5M | 2.0M | 1.9M | 1.9M | |
| Ebit | (8.9M) | (67.3M) | (128.9M) | (95.6M) | (86.5M) | (90.8M) | |
| Research Development | 21.8M | 48.2M | 96.8M | 64.4M | 59.4M | 47.3M | |
| Ebitda | (22.9M) | (66.7M) | (126.7M) | (92.3M) | (86.0M) | (90.3M) | |
| Income Before Tax | (35.3M) | (67.3M) | (125.6M) | (88.9M) | (82.4M) | (86.6M) | |
| Net Income | (41.1M) | (65.5M) | (123.2M) | (84.5M) | (82.4M) | (86.6M) | |
| Income Tax Expense | 5.9M | (1.8M) | (2.4M) | (4.4M) | (4.0M) | (3.8M) |
Black Diamond Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Black Diamond Therap. It measures of how well Black is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Black Diamond brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Black had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Black Diamond has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (281.5M) | (281.7M) | 133.3M | 53.5M | 16.3M | 17.2M | |
| Change In Cash | 103.1M | (118.9M) | 31.2M | (31.5M) | 21.6M | 22.6M | |
| Free Cash Flow | (24.7M) | (52.3M) | (102.9M) | (85.3M) | (66.8M) | (70.1M) | |
| Depreciation | 47K | 52K | 205K | 508K | 437K | 458.9K | |
| Other Non Cash Items | 6.4M | 524K | 2.0M | 3.3M | 2.0M | 2.3M | |
| Capital Expenditures | 21K | 142K | 2.7M | 192K | 33K | 31.4K | |
| Net Income | (35.3M) | (67.3M) | (125.6M) | (91.2M) | (82.4M) | (86.6M) | |
| End Period Cash Flow | 154.7M | 35.8M | 67.0M | 35.5M | 57.0M | 64.4M | |
| Change To Netincome | 10.1M | 10.0M | 18.2M | 12.2M | 14.0M | 9.4M |
Black Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Black Diamond's current stock value. Our valuation model uses many indicators to compare Black Diamond value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Black Diamond competition to find correlations between indicators driving Black Diamond's intrinsic value. More Info.Black Diamond Therapeutics is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Black Diamond's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Black Diamond's earnings, one of the primary drivers of an investment's value.Black Diamond Therap Systematic Risk
Black Diamond's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Black Diamond volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Black Diamond Therap correlated with the market. If Beta is less than 0 Black Diamond generally moves in the opposite direction as compared to the market. If Black Diamond Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Black Diamond Therap is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Black Diamond is generally in the same direction as the market. If Beta > 1 Black Diamond moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Black Diamond Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Black Diamond's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Black Diamond growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Black Diamond December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Black Diamond help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Black Diamond Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Black Diamond Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Black Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Black Diamond's daily price indicators and compare them against related drivers.
| Information Ratio | (0.31) | |||
| Maximum Drawdown | 19.51 | |||
| Value At Risk | (8.30) | |||
| Potential Upside | 5.47 |
Additional Tools for Black Stock Analysis
When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.